Application of the ANP to the prioritization of project stakeholders in the context of responsible research and innovation

[EN] This paper presents a methodology to assess the stakeholders¿ influence in a research project within the context of responsible research and innovation. The methodology is based on a combination of the multicriteria decision making technique analytic network process and the key areas of responsible research. The method allows ranking and ordering the project¿s stakeholders based on their influence upon its responsibility. The purpose of such an assessment is to help research teams to more efficiently devote their limited resources to stakeholder management. The procedure is applied to a case study of the Information and Communication Technology business sector. It is an ongoing project at an early phase of development. Influential stakeholders have been identified first, and have been further classified into groups based on their relative importance. The assessment of their influence has been based on up to 16 different criteria, mainly belonging to the framework of responsible research and innovation. In the case study, the most influential criterion was the Capability to promote public engagement, while Developers were found to be the stakeholders most contributing to the research project responsibility. However, as explained, this is a temporary situation, valid for the current project development situation. It may vary over time as criteria vary in weight and stakeholders vary in influence.The authors would like to thank to our anonymous referees for their constructive comments and suggestions that helped us to improve the quality of the paper. Also, to the “Bolívar Gana con Ciencia” program from the Gobernación de Bolívar (Colombia) for the financial support. For the same reason, the authors are grateful to the Spanish Agencia Estatal de Investigación for its support of the project Propuesta de Indicadores para Impulsar el Diseño de Una Política Orientada al Desarrollo de Investigación e Innovación Responsable en España (CSO2016-76828-R)Ligardo-Herrera, I.; Gómez-Navarro, T.; Gonzalez-Urango, H. (2018). Application of the ANP to the prioritization of project stakeholders in the context of responsible research and innovation. Central European Journal of Operations Research. 1-23. https://doi.org/10.1007/s10100-018-0573-4S123Akbari N, Irawan CA, Jones DF, Menachof D (2017) A multi-criteria port suitability assessment for developments in the offshore wind industry. Renew Energy 102:118–133. https://doi.org/10.1016/j.renene.2016.10.035Aragonés-Beltrán P, García-Melón M, Montesinos-Valera J (2017) How to assess stakeholders’ influence in project management? A proposal based on the analytic network process. Int J Proj Manag. https://doi.org/10.1016/j.ijproman.2017.01.001Barrios Ortiz MA, De Felice F, Negrete KP et al (2016) An AHP-topsis integrated model for selecting the most appropriate tomography equipment. Int J Inf Technol Decis Mak 15:861–885. https://doi.org/10.1142/S021962201640006XBhupendra KV, Sangle S (2017) What drives successful implementation of product stewardship strategy? The role of absorptive capability. Corp Soc Responsib Environ Manag 24:186–198. https://doi.org/10.1002/csr.1394Botero C, Pereira C, Tosic M, Manjarrez G (2015) Design of an index for monitoring the environmental quality of tourist beaches from a holistic approach. Ocean Coast Manag 108:65–73. https://doi.org/10.1016/j.ocecoaman.2014.07.017Brugha R (2000) Stakeholder analysis: a review. Health Policy Plan 15:239–246. https://doi.org/10.1093/heapol/15.3.239Burget M, Bardone E, Pedaste M (2017) Definitions and conceptual dimensions of responsible research and innovation: a literature review. Sci Eng Ethics. https://doi.org/10.1007/s11948-016-9782-1Caballero-Luque A, Aragonés-Beltrán P, García-Melón M, Dema-Pérez C (2010) Analysis of the alignment of Company goals to Web content using ANP. Int J Inf Technol Decis Mak 9:419–436. https://doi.org/10.1142/S0219622010003889Claudia K, Köppl A, Stagl S (2014) Towards an operational measurement of socio-ecological performance. Working Paper no 52Colin E, Ackermann F (1998) Making strategy: the journey of strategic management. SAGE Publications Ltd, LondonDahlsrud A (2006) How corporate social responsibility is defined: an analysis of 37 definitions. Corp Soc Responsib Environ Manag 13:1–13. https://doi.org/10.1002/csrde Jong IM, Kupper F, Broerse J (2016) Inclusive deliberation and action in emerging RRI practices: the case of neuroimaging in security management. J Responsib Innov 3:26–49. https://doi.org/10.1080/23299460.2015.1137752De Lopez T (2001) Stakeholder management for conservation projects: a case study of Ream National Park, Cambodia. J Environ Manag 28:47–60De Lotto R, Gazzola V, Gossenberg S et al (2016) Proposal to reduce natural risks: analytic network process to evaluate efficiency of city planning strategies. Springer, Cham, pp 650–664European Commission (2011) DG Research workshop on Responsible Research & Innovation in EuropeGeoghegan-Quinn M (2012) Responsible research and innovation. Europe’s ability to respond to societal challengesGörener A (2012) Comparing AHP and ANP: an application of strategic decisions making in a Manufacturing Company. Int J Bus Soc Sci 3:194–208Jaafari A, Najafi A, García-Melón M (2015) Decision-making for the selection of a best wood extraction method: an analytic network process approach. For Policy Econ 50:200–209. https://doi.org/10.1016/j.forpol.2014.09.010Koops BJ (2015) The concepts, approaches, and applications of responsible innovations: an introduction. In: Koops BJ, Oosterlaken I, Romijn H, Swierstra T, van den Hoven J (eds) Responsible innovation 2: concepts, approaches, and applications. Springer, Dordrecht, pp 1–15Ligardo-Herrera I, Gómez-Navarro T, Inigo EA, Blok V (2018) Addressing climate change in responsible research and innovation: recommendations for its operationalization. Sustainability 10:20. https://doi.org/10.3390/su10062012Lubberink R, Blok V, van Ophem J, Omta O (2017) Lessons for responsible innovation in the business context: a systematic literature review of responsible, social and sustainable innovation practices. Sustainability. https://doi.org/10.3390/su9050721Mitchell RK, Agle BR, Wood DJ (1997) Toward a theory of stakeholder identification and salience: defining the principle of who and what really. Acad Manag Rev 22:853–886. https://doi.org/10.5465/AMR.1997.9711022105Owen R, Bessant J, Heintz M (2013) Responsible innovation: managing the responsible emergence of science and innovation in society. Wiley, New YorkPeris J, García-Melón M, Gómez-Navarro T, Calabuig C (2013) Prioritizing local agenda 21 programmes using analytic network process: a Spanish case study. Sustain Dev 21:338–352. https://doi.org/10.1002/sd.514Ramzan N, Degenkolbe S, Witt W (2008) Evaluating and improving environmental performance of HC’s recovery system: a case study of distillation unit. Chem Eng J 140:201–213. https://doi.org/10.1016/j.cej.2007.09.042Rosso M, Bottero M, Pomarico S et al (2014) Integrating multicriteria evaluation and stakeholders analysis for assessing hydropower projects. Energy Policy 67:870–881. https://doi.org/10.1016/j.enpol.2013.12.007Saaty TL (1990) How to make a decision: the analytic hierarchy process. Eur J Oper Res 48:9–26. https://doi.org/10.1016/0377-2217(90)90057-ISaaty TL (1994) How to make a decision: the analytic hierarchy process. Interfaces (Providence) 24:19–43Saaty TL (2001) The analytic network process: decision making with dependence and feedback. RWS Publications, PittsburghSaaty TL (2005) Theory and applications of the analytic network process: decision making with benefits, opportunities, costs, and risks. The Analytic Hierarchy Process (AHP) and its generalization to dependence and feedback, the Analytic Network Process (ANP), are methods of relative measurement of tangibles and intangibles. Being able to derive such measurements is essential for making goSaaty TL (2008) Decision making with the analytic hierarchy process. Int J Serv Sci 1:83. https://doi.org/10.1504/IJSSCI.2008.017590Saaty TL, Peniwati K (2008) Group decision making : drawing out and reconciling differences. RWS Publications, PittsburghSangle S, Babu PR (2007) Evaluating sustainability practices in terms of stakeholders’ satisfaction. Int J Bus Gov Ethics 3:56. https://doi.org/10.1504/IJBGE.2007.011934Shiau TA, Chuen-Yu JK (2016) Developing an indicator system for measuring the social sustainability of offshore wind power farms. Sustainability. https://doi.org/10.3390/su8050470Šijanec M, Žarnić R, Šelih J (2009) Multicriterial sustainability assessment of residential buildings. Technol Econ Dev Econ 15:612–630. https://doi.org/10.3846/1392-8619.2009.15.612-630Sipahi S, Timor M (2010) The analytic hierarchy process and analytic network process: an overview of applications. Manag Decis 48:775–808. https://doi.org/10.1108/00251741011043920Sólnes J (2003) Environmental quality indexing of large industrial development alternatives using AHP. Environ Impact Assess Rev 23:283–303. https://doi.org/10.1016/S0195-9255(03)00004-0Stahl BC, Coeckelbergh M (2016) Ethics of healthcare robotics: towards responsible research and innovation. Rob Auton Syst 86:152–161. https://doi.org/10.1016/j.robot.2016.08.018Stilgoe J, Owen R, Macnaghten P (2013) Developing a framework for responsible innovation. Res Policy 42:1568–1580. https://doi.org/10.1016/j.respol.2013.05.008Strand R, Spaapen J, Bauer MW et al (2015) Indicators for promoting and monitoring responsible research and innovation report from the expert group on policy indicatorsVaidya OS, Kumar S (2006) Analytic hierarchy process: an overview of applications. Eur J Oper Res 169:1–29. https://doi.org/10.1016/j.ejor.2004.04.028van de Poel I, Asveld L, Flipse S et al (2017) Company strategies for responsible research and innovation (RRI): a conceptual model. Sustainability 9:2045. https://doi.org/10.3390/su9112045Von Schomberg R (2011) Prospects for technology assessment in a framework of responsible research and innovation. Tech abschätzen lehren Bild transdisziplinärer Methoden. https://doi.org/10.1007/978-3-531-93468-6_2Wu X, Cui P (2016) A study of the time-space evolution characteristics of urban-rural integration development in a mountainous area based on ESDA-GIS: the case of the Qinling-Daba mountains in China. Sustainability 8:1085. https://doi.org/10.3390/su8111085Yüksel I, Dagdeviren M (2007) Using the analytic network process (ANP) in a SWOT analysis—a case study for a textile firm. Inf Sci (NY) 177:3364–3382. https://doi.org/10.1016/j.ins.2007.01.00

Global, regional, and national burden of chronic kidney disease, 1990–2017 : a systematic analysis for the Global Burden of Disease Study 2017

Background Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. Methods The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool, and included incidence, prevalence, years lived with disability, mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function. Findings Globally, in 2017, 1·2 million (95% uncertainty interval [UI] 1·2 to 1·3) people died from CKD. The global all-age mortality rate from CKD increased 41·5% (95% UI 35·2 to 46·5) between 1990 and 2017, although there was no significant change in the age-standardised mortality rate (2·8%, −1·5 to 6·3). In 2017, 697·5 million (95% UI 649·2 to 752·0) cases of all-stage CKD were recorded, for a global prevalence of 9·1% (8·5 to 9·8). The global all-age prevalence of CKD increased 29·3% (95% UI 26·4 to 32·6) since 1990, whereas the age-standardised prevalence remained stable (1·2%, −1·1 to 3·5). CKD resulted in 35·8 million (95% UI 33·7 to 38·0) DALYs in 2017, with diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected. 1·4 million (95% UI 1·2 to 1·6) cardiovascular disease-related deaths and 25·3 million (22·2 to 28·9) cardiovascular disease DALYs were attributable to impaired kidney function. Interpretation Kidney disease has a major effect on global health, both as a direct cause of global morbidity and mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI

Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study

We conducted an international study of idiopathic pulmonary fibrosis (IPF) diagnosis among a large group of physicians and compared their diagnostic performance to a panel of IPF experts. A total of 1141 respiratory physicians and 34 IPF experts participated. Participants evaluated 60 cases of interstitial lung disease (ILD) without interdisciplinary consultation. Diagnostic agreement was measured using the weighted kappa coefficient (\u3baw). Prognostic discrimination between IPF and other ILDs was used to validate diagnostic accuracy for first-choice diagnoses of IPF and were compared using the Cindex. A total of 404 physicians completed the study. Agreement for IPF diagnosis was higher among expert physicians (\u3baw=0.65, IQR 0.53-0.72, p20 years of experience (C-index=0.72, IQR 0.0-0.73, p=0.229) and non-university hospital physicians with more than 20 years of experience, attending weekly MDT meetings (C-index=0.72, IQR 0.70-0.72, p=0.052), did not differ significantly (p=0.229 and p=0.052 respectively) from the expert panel (C-index=0.74 IQR 0.72-0.75). Experienced respiratory physicians at university-based institutions diagnose IPF with similar prognostic accuracy to IPF experts. Regular MDT meeting attendance improves the prognostic accuracy of experienced non-university practitioners to levels achieved by IPF experts

Laparoscopy in management of appendicitis in high-, middle-, and low-income countries: a multicenter, prospective, cohort study.

BACKGROUND: Appendicitis is the most common abdominal surgical emergency worldwide. Differences between high- and low-income settings in the availability of laparoscopic appendectomy, alternative management choices, and outcomes are poorly described. The aim was to identify variation in surgical management and outcomes of appendicitis within low-, middle-, and high-Human Development Index (HDI) countries worldwide. METHODS: This is a multicenter, international prospective cohort study. Consecutive sampling of patients undergoing emergency appendectomy over 6 months was conducted. Follow-up lasted 30 days. RESULTS: 4546 patients from 52 countries underwent appendectomy (2499 high-, 1540 middle-, and 507 low-HDI groups). Surgical site infection (SSI) rates were higher in low-HDI (OR 2.57, 95% CI 1.33-4.99, p = 0.005) but not middle-HDI countries (OR 1.38, 95% CI 0.76-2.52, p = 0.291), compared with high-HDI countries after adjustment. A laparoscopic approach was common in high-HDI countries (1693/2499, 67.7%), but infrequent in low-HDI (41/507, 8.1%) and middle-HDI (132/1540, 8.6%) groups. After accounting for case-mix, laparoscopy was still associated with fewer overall complications (OR 0.55, 95% CI 0.42-0.71, p < 0.001) and SSIs (OR 0.22, 95% CI 0.14-0.33, p < 0.001). In propensity-score matched groups within low-/middle-HDI countries, laparoscopy was still associated with fewer overall complications (OR 0.23 95% CI 0.11-0.44) and SSI (OR 0.21 95% CI 0.09-0.45). CONCLUSION: A laparoscopic approach is associated with better outcomes and availability appears to differ by country HDI. Despite the profound clinical, operational, and financial barriers to its widespread introduction, laparoscopy could significantly improve outcomes for patients in low-resource environments. TRIAL REGISTRATION: NCT02179112

Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018

Abstract: Exclusive breastfeeding (EBF)—giving infants only breast-milk for the first 6 months of life—is a component of optimal breastfeeding practices effective in preventing child morbidity and mortality. EBF practices are known to vary by population and comparable subnational estimates of prevalence and progress across low- and middle-income countries (LMICs) are required for planning policy and interventions. Here we present a geospatial analysis of EBF prevalence estimates from 2000 to 2018 across 94 LMICs mapped to policy-relevant administrative units (for example, districts), quantify subnational inequalities and their changes over time, and estimate probabilities of meeting the World Health Organization’s Global Nutrition Target (WHO GNT) of ≥70% EBF prevalence by 2030. While six LMICs are projected to meet the WHO GNT of ≥70% EBF prevalence at a national scale, only three are predicted to meet the target in all their district-level units by 2030

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events